Technical Analysis for NUVB - Nuvation Bio Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 3.30 | 0.00% | 0.00 |
NUVB closed unchanged on Wednesday, May 15, 2024, on 1.8 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Jun 3
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Wide Bands | Range Expansion | -2.08% | |
| Overbought Stochastic | Strength | -2.08% | |
| Wide Bands | Range Expansion | 1.54% | |
| Overbought Stochastic | Strength | 1.54% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 8 hours ago |
| Outside Day | about 8 hours ago |
| Fell Below Previous Day's Low | about 8 hours ago |
| Down 1% | about 8 hours ago |
| Gap Up Closed | about 9 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/03/2024
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.1598 |
| 52 Week Low | 0.95 |
| Average Volume | 1,664,417 |
| 200-Day Moving Average | 1.85 |
| 50-Day Moving Average | 2.88 |
| 20-Day Moving Average | 3.01 |
| 10-Day Moving Average | 3.26 |
| Average True Range | 0.21 |
| RSI (14) | 60.47 |
| ADX | 29.22 |
| +DI | 33.01 |
| -DI | 13.05 |
| Chandelier Exit (Long, 3 ATRs) | 2.92 |
| Chandelier Exit (Short, 3 ATRs) | 3.13 |
| Upper Bollinger Bands | 3.59 |
| Lower Bollinger Band | 2.44 |
| Percent B (%b) | 0.75 |
| BandWidth | 38.35 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.12 |
| MACD Histogram | 0.0186 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.74 | ||||
| Resistance 3 (R3) | 3.77 | 3.66 | 3.66 | ||
| Resistance 2 (R2) | 3.66 | 3.55 | 3.64 | 3.64 | |
| Resistance 1 (R1) | 3.48 | 3.48 | 3.43 | 3.45 | 3.61 |
| Pivot Point | 3.37 | 3.37 | 3.34 | 3.35 | 3.37 |
| Support 1 (S1) | 3.19 | 3.26 | 3.14 | 3.16 | 2.99 |
| Support 2 (S2) | 3.08 | 3.19 | 3.06 | 2.96 | |
| Support 3 (S3) | 2.90 | 3.08 | 2.94 | ||
| Support 4 (S4) | 2.87 |
